Trials / Recruiting
RecruitingNCT05646381
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 502 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pelacarsen (TQJ230) 80mg | Pelacarsen (TQJ230) 80mg |
| DRUG | Matching placebo | Matching placebo |
Timeline
- Start date
- 2024-03-07
- Primary completion
- 2030-03-12
- Completion
- 2030-03-12
- First posted
- 2022-12-12
- Last updated
- 2026-04-15
Locations
139 sites across 15 countries: United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05646381. Inclusion in this directory is not an endorsement.